Defense Secretary Pete Hegseth’s drive to build a more physically formidable, “High‑T” force has opened a new front in US civil–military debates, pitting performance ambitions and culture‑war rhetoric against cautious medical consensus and ethical concerns.

July 15: Policy unveiled amid culture-war backdrop

On July 15, Hegseth’s team briefed reporters that US troops “will soon receive testosterone treatment” as part of a push to make them stronger, a move framed against a wider right‑wing focus on declining sperm counts and male virility.¹ The policy positioned hormone therapy as a tool to enhance physical strength and overall well‑being in the armed forces.¹

July 17: Mandatory “Low-T” screening announced

Two days later, Hegseth released a short video declaring that all active duty and reserve personnel aged 30 and older will undergo mandatory yearly screening for testosterone deficiency, with younger troops allowed to opt in.² He insisted the program is not about “artificial enhancement” but about “restoring and optimizing” capabilities and ensuring troops have the “biological foundation required to sustain the fight.”²

Endocrinologists push back

The announcement triggered immediate alarm among hormone specialists. The Endocrine Society stated there is “insufficient evidence to support a general recommendation to perform population-level screening for hypogonadism in asymptomatic men,” warning that wide testing invites misdiagnosis and unnecessary treatment.²

Professor Bradley Anawalt, an endocrinologist at the University of Washington, called the plan “a great big fat ‘Oh, no,’” arguing that “we’re turning the clock back on rational healthcare” and raising fears over ethics, health consequences, and incorrect assessments.²

Clash of priorities: readiness vs. risk

Supporters inside the Pentagon see testosterone screening as a relatively low‑cost way to improve resilience, longevity, and combat readiness.² Medical experts counter that the science behind broad screening and testosterone replacement therapy in healthy or minimally symptomatic men is uncertain and that potential side effects could undermine, not enhance, long‑term troop health.²

As implementation plans move forward, the Pentagon now faces twin tests: proving the program’s benefits for military performance and reassuring skeptical clinicians that it will not turn frontline medicine into a political experiment.